A new medical trial showed promising results as scientists seek a breakthrough to treat Huntington's disease , according to research team based in the United Kingdom .

The clinical drug trial by University College London tested new gene therapy AMT-130, finding 75% less progression of the disease among trial participants over 36 months, the college announced Sept. 24.

"This result changes everything. On the basis of these results it seems likely AMT-130 will be the first licensed treatment to slow Huntington’s disease, which is truly world-changing stuff," UCL neurology professor Ed Wild, principal investigator on the trial, said. "If that happens, we need to work hard to make it available to everyone who needs it, while working no less diligently to add more effective treatments

See Full Page